Rezolute, Inc. (NasdaqCM: RZLT)
Health Care · Biotechnology · US
$5.09
+10.65% today · -27.3% 1Y
Rezolute, Inc. (NasdaqCM: RZLT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $531.74M and employs 68 people.
Over the last twelve months the share price has lost 27.3%, trading between 1.07 and 11.46.
Tweenvest scores Rezolute, Inc. across four factors: quality 27/100. Its strongest factor is quality.
RZLT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $531.74M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.80
- Dividend yield
- —
- Beta (5Y)
- 0.62
- 52-week high
- $11.46
- 52-week low
- $1.07
- Avg volume (3M)
- —
- Shares outstanding
- 104.47M
- Employees
- 68
- Next earnings
- —
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
- ISIN
- US76200L3096
- Founded
- 2010
- Listed since
- Jan 14, 2013
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.